Scion Accuses Abbott Of Misappropriating Clo-Sur Wound Dressing Secrets
This article was originally published in The Gray Sheet
Scion Cardio-Vascular, Inc. is accusing Abbott Laboratories of lifting elements of its Clo-Sur P.A.D. marketing campaign, among other infractions, in a six-count complaint filed Nov. 22 in Miami federal court
You may also be interested in...
Scion Cardio-Vascular drops suit accusing Abbott of misappropriating Clo-Sur P.A.D. wound dressing trade secrets. The firm says it will conserve resources for marketing efforts (1"The Gray Sheet" Dec. 9, 2002, p. 18)...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.